IP Library › Granted Patent US 7,906,549
Granted Patent B2
US 7,906,549 · App. 11/721,601 · Granted Mar 15, 2011

Aminocarboxylic acid derivative and medicinal use thereof

Assignee: Ono Pharmaceutical Co., Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,906,549
App. No.
11/721,601
Granted
Mar 15, 2011
Kind
B2
Abstract

The present invention relates to a compound represented by the formula (I), a salt thereof, an N-oxide form thereof, a solvate thereof, or a prodrug thereof, and a medicament containing the same. The compound represented by the formula (I) has an ability to bind to an S1P receptor (particularly, EDG-1, EDG-6, and/or EDG-8) and is useful for preventing and/or treating for rejection to transplantation, graft-versus-host disease, autoimmune diseases, allergic diseases, neurodegenerating diseases, and the like. wherein all symbols are described in the specification.

Claims (12)

1. 1-({6-[(2-methoxy-4-propylbenzyl)oxy]-1-methy 1-3,4-dihydro-2-naphthalenyl}methyl)-3-azetidinecarboxylic acid, a salt thereof, an N-oxide form thereof, a hydrate thereof or a prodrug thereof.

2. The compound according to claim 1 , which is selected from the group consisting of

(1) 1-({6-[(2-methoxy-4-propylbenzyl)oxy]-1-methy 1-3,4-dihydro-2-naphthalenyl}methyl)-3-azetidinecarboxylic acid,

(2) ethyl 1-({6-[(2-methoxy-4-propylbenzyl)oxy]-1-methy 1-3,4-dihydro-2-naphthalenyl}methyl)-3-azetidinecarboxylate,

(3) 1-({6-[(2-methoxy-4-propylbenzyl)oxy]-1-methy 1-3,4-dihydro-2-naphthalenyl}methyl)-3-azetidinecarboxylic acid monohydrate,

(4) 1-({6-[(2-methoxy-4-propylbenzyl)oxy]-1-methy 1-3,4-dihydro-2-naphthalenyl}methyl)-3-azetidinecarboxylic acid hydrochloride,

(5) sodium 1-({6-[(2-methoxy-4-propylbenzyl)oxy]-1-methy 1-3,4-dihydro-2-naphthalenyl}methyl)-3-azetidinecarboxylate,

(6) potassium 1-({6-[(2-methoxy-4-propylbenzyl)oxy]-1-methyl-3,4-dihydro-2-naphthalenyl}methyl)-3-azetidinecarboxylate,

(7) 1-({6-[(2-methoxy-4-propylbenzyl)oxy]-1-methy 1-3,4-dihydro-2-naphthalenyl}methyl)-3-azetidinecarboxylic acid hemicalcium salt, and

(8) 1-({6-[(2-methoxy-4-propylbenzyl)oxy]-1-methyl-3,4-dihydro-2-naphthalenyl} methy 1)-3-azetidinecarboxylic acid 1-oxide.

3. A compound which is 1-({6-[(2-methoxy-4-propylbenzyl)oxy]-1-methyl-3,4-dihydro-2-naphthalenyl}methyl)-3-azetidinecarboxylic acid.

4. A pharmaceutical composition which comprises the compound according to claim 1 , a salt thereof, an N-oxide form thereof, a hydrate thereof, or a prodrug thereof.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 13, 2007
From: HABASHITA, HIROMU; KURATA, HARUTO; NAKADE, SHINJI
To: ONO PHARMACEUTICAL CO., LTD
Reel/Frame 019423/0323 →
Priority Claims (3)
JP 2004-360539 · Dec 13, 2004 · national
JP 2005-125740 · Apr 22, 2005 · national
JP 2005-233790 · Aug 11, 2005 · national
Continuity (1)
Related Publication 20090275554A1 · Nov 5, 2009